On May 18, 2017 Portola Pharmaceuticals Inc. (Nasdaq:PTLA) reported that preclinical and clinical data on cerdulatinib in relapsed/refractory b-cell malignancies will be presented at the European Hematology Association (EHA) (Free EHA Whitepaper), which is taking place from June 22-25 in Madrid, Spain (Press release, Portola Pharmaceuticals, MAY 18, 2017, View Source [SID1234519238]). Schedule your 30 min Free 1stOncology Demo! Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details regarding the presentations follow.
Oral Presentation Details:
Presentation Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Complete Inhibition of SYK and JAK and Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B Cell Malignancies
Presenter: Paul Hamlin, M.D., Memorial Sloan-Kettering Cancer Center
Abstract Number: EHA (Free EHA Whitepaper)22
Presentation Date and Time: June 25, 2017 from 9:00-9:15 a.m. UTC
Location: Hall A
Poster Presentation Details:
Presentation Title: IL-4 Increases Expression of Positive Regulators of BCR Signaling in CLL Which Can Be Overcome by Cerdulatinib
Presenter: Andrew Steele, Ph.D., Associate Professor, Medicine, University of Southampton
Abstract Number: P587
Presentation Date and Time: June 24, 2017 from 5:30 – 6:00 p.m. UTC
Location: Poster Hall (Hall 7)